Abstract:Immunostimulatory cues play an important role in priming antitumor immunity and promoting the efficacy of subunit cancer vaccines. However, the clinical use of many immunostimulatory agents is often hampered by their inefficient in vivo delivery which may decrease immune response to the vaccination. To promote vaccine efficacy, we develop vaccine formulations which integrate three key elements: (1) a nano-adjuvant formulated by conjugating an agonistic anti-CD40 monoclonal antibody (αCD40) to the surface of a polyIC-loaded lipid nanoparticle, (2) a peptide amphiphile containing an optimized CD8 + T-cell epitope that derived from a melanoma antigen gp100, (3) an agonistic anti-4-1BB monoclonal antibody (α4-1BB) that boosts the efficacy of vaccinations. In a syngeneic mouse model of melanoma, the vaccine formulations enhanced innate immunity and activated multiple innate immune signaling pathways within draining lymph nodes, as well as promoted antigen-specific immune responses and reduced immunosuppression in the tumor microenvironment, leading to profound tumor growth inhibition and prolonged survival. Thus, our vaccine formulations represent an attractive strategy to stimulate antitumor immunity and control tumor progression. Statement of significance The clinical use of many immunostimulatory agents is often hampered by their inefficient in vivo delivery which may decrease immune response to the vaccination. To promote the antitumor immunity of subunit vaccines, we develop novel vaccine formulations that integrate multifunctional modalities including (1) a nano-adjuvant containing anti-CD40 monoclonal antibody (αCD40) and TLR3 agonist which activate innate immunity through diverse signaling pathways, (2) a peptide amphiphile containing an optimized CD8 + T-cell epitope from tumor antigen, (3) an anti-4-1BB monoclonal antibody (α4-1BB) that boosts the efficacy of vaccinations. In this study, our vaccine formulations stimulate superior antitumor immunity and control tumor progression. The above nano-engineered platform and immunogenic biomacromolecules can be further applied to other T-cell-inducing vaccines.

A novel fluoropolymer as a protein delivery vector with robust adjuvant effect for cancer immunotherapy.

A Fluorinated Supramolecular Self‐Assembled Peptide as Nanovaccine Adjuvant for Enhanced Cancer Vaccine Therapy

A general strategy towards personalized nanovaccines based on fluoropolymers for post-surgical cancer immunotherapy

Nanovaccine Based on a Protein-Delivering Dendrimer for Effective Antigen Cross-Presentation and Cancer Immunotherapy

Polymer‐Protein Nanovaccine Synthesized via Reactive Self‐Assembly with Potential Application in Cancer Immunotherapy: Physicochemical And Biological Characterization In Vitro And in Vivo

Mannosylated Fluoropolypeptide Nanovaccines Remodeling Tumor Immunosuppressive Microenvironment to Achieve Highly Potent Cancer Immunotherapy

Fluoroamphiphiles for enhancing immune response of subunit vaccine against SARS-CoV-2

A Fluorinated Supramolecular Self‐Assembled Peptide As Nanovaccine Adjuvant for Enhanced Cancer Vaccine Therapy (small Methods 5/2023)

Bio-membrane Adhesive Poly(choline Phosphate L-glutamate)-based Nanoparticles As Vaccine Delivery Systems for Cancer Immunotherapy

Self-adjuvanting Polymeric Nanovaccines Enhance IFN Production and Cytotoxic T Cell Response.

Fluoroalkane modified cationic polymers for personalized mRNA cancer vaccines

Glycopolypeptide Coordinated Nanovaccine: Fabrication, Characterization, and Antitumor Immune Response

Nano-adjuvants and immune agonists promote antitumor immunity of peptide amphiphiles

Fluoropolymers for intracellular and in vivo protein delivery.

Polymer nanoparticles as adjuvants in cancer immunotherapy

A Nanovaccine Based on Adjuvant Peptide FK‐13 and l‐Phenylalanine Poly(ester amide) Enhances CD8+ T Cell‐Mediated Antitumor Immunity

Farnesylthiosalicylic acid-derivatized PEI-based nanocomplex for improved tumor vaccination

Cancer Vaccines Using Supramolecular Hydrogels of NSAID-modified Peptides As Adjuvants Abolish Tumorigenesis.

Fluorinated Redox-Responsive Poly(amidoamine) As a Vaccine Delivery System for Antitumor Immunotherapy.

Uplifting Antitumor Immunotherapy with Lymph-Node-Targeted and Ratio-Controlled Codelivery of Tumor Cell Lysate and Adjuvant

Dual-responsive Nanovaccine for Cytosolic Delivery of Antigens to Boost Cellular Immune Responses and Cancer Immunotherapy